The way to prevent inflammatory diseases of the upper respiratory tract

 

(57) Abstract:

The invention relates to medicine, to otolaryngology, for the treatment of inflammatory diseases of the upper respiratory tract. Enter the capsular polysaccharide antigen of Haemophilus ifluenzae type b intranasal six times 1 time in three days in a dose of 0.2 ml at a rate of 1 mg/ml. This method can prevent the development of inflammation in the upper respiratory tract, as well as the possibility of complications.

The invention relates to medicine, namely, otorhinolaryngology, and will find application in the treatment of inflammatory diseases of the upper respiratory tract.

Inflammatory diseases of the upper respiratory tract are quite common pathology leading to disability, disability, and often fatal. These diseases are directly related to the presence of the mucous membranes of the respiratory tract of many bacteria, viruses and other microorganisms that by reducing the reactivity of the microorganism present the risk of inflammatory diseases. One group of such infectious agents are conditionally pathogenic microorganisms.

Among platanaceae - Pffeifer (synonyms - Haemophilus influenzae, Hemophilus or wand influenza, Hi), a potential human pathogen, especially dangerous for young children and school age. Particularly susceptible Haemophilus influenzae children attending organised pre-school institutions, children living in orphanages, institutions, and students. The rapid spread of the microorganism associated with the transfer of its airborne. Haemophilus influenzae can cause meningitis, septicaemia, pneumonia, bronchitis, asthma and rhinitis, infectious-allergic forms of cellulite, tinuity and so on Haemophilus influenzae serotype b plays a significant role in infectious diseases of man and is the causative agent of a large number of acute and chronic inflammatory diseases in children and adults.

Studies on patent and scientific and medical literature identified various methods of treatment of inflammatory diseases of the nasal cavity and paranasal sinuses.

A. Century Pidaev et al. (Methodological principles of continuous rehabilitation therapy of patients with chronic rhinosinusitis and pathology of the pulmonary system //Rossick. rhinology.- 1996.- N 2-3.-S. 129-130) for treatment of patients with chronic inflammatory is Adorno resort and long-term exercise therapy therapy. The analysis of treatment group patients showed that of the 56 patients recovered 14, produced a significant improvement - 23, improvement - in 8. The effect of the treatment was absent in 11 patients.

N. To.Sangarovskaya, and I. Melnikov (Using rulide in the treatment of acute rhinosinusitis //Rossick. rhinology.- 1997. N 2. S. 46) used the antibiotic ruled (roxithromycin) in patients with acute insinuate. The authors consider the effect of the drug is quite effective for most patients.

Y. A. Djamaludinov et al. (The use of ribomunil for the prevention of relapse in patients with chronic rhinosinusitis //Rossick. rhinology.- 1996.- N 2-3. - S. 27-28) serves to prevent chronic inflammatory diseases of the upper respiratory tract ribosomal drug ribomunyl and celebrate when it is used to reduce the need for patients in antibacterial drugs in the acute exacerbation of process.

The disadvantages of all the other ones is the possibility of complications, leading to long-term disability, disability or death.

As the prototype used a method comprising warning inflammatory zabolevanii. 35) offers parenteral to administer the vaccine, derived from the capsular polysaccharide antigen of Haemophilus influenzae type b.

This method is important disadvantages:

1. introduction vaccination of the drug;

2. the use of the parenteral route of administration of the drug, not excluding the possibility of developing certain complications.

The aim of the present invention is the prevention of inflammatory diseases of the upper respiratory tract.

Goal is achieved by six injections into the nasal cavity of the patient 1 every 3 days single dose capsular polysaccharide antigen of Haemophilus influenzae type b in solution with a volume of 0.2 ml at a rate of 1 mg/ml.

However, in order to move on to the presentation of our proposed method, it is necessary to briefly dwell on some of the preconditions for its implementation.

Haemophilus influenzae has long been recognized as the main cause severe infections and mortality in children aged less than 5 years. The results of the study Haemophilus influenzae, conducted in many countries and on many continents, have allowed researchers to come to a single conclusion: Haemophilus influenzae is an important public health problem almost everywhere. Wide rasprostranenie early age to confirm this. An effective way of dealing with Hib infection is specific vaccine against the most susceptible populations. Immunization of infants and children is the most effective strategy to reduce morbidity. Particularly aggressive disease caused by Haemophilus influenzae type b.

We have conducted two groups of experiments.

Experiment 1 consisted of the following: 12 were selected outbred rats at the age of 4-6 months. weighing 350 - 400 g each, divided into 2 groups of 9 animals in the first and 3 in the second. The second group of animals was control. The first group of animals consisting of 9 rats were injected in the nasal cavity the culture of Haemophilus influenzae type b in solution with a volume of 0.2 cm3containing 500 million microbial phone Animals, 3 of the first group and 1 from the second, was deceptional under ether anesthesia at 5, 7 and 14 days after the beginning of the experiment. From the surface of the mucous membrane of the nasal cavity (each half separately), the Oro - and nasopharynx, ethmoid sinuses with a swab produced biopsy specimens for bacteriological examination. Sowing microflora produced on chocolate agar, cultured in thermostat during the day and on the second day produced asknih ways took fragments of mucosa for the study of morphological structure. The mucous membranes were fixed in 12% solution of neutral formalin. Paraffin sections were stained with hematoxylin-eosin and van gieson.

In smears obtained on day 5 since the beginning of the experiment with the mucosa of the animals of the first group found a single colonies of Haemophilus influenzae type b, and histological examination did not show any changes typical of the inflammatory process.

In smears from the mucous membranes of Oro - and nasopharynx, received on the 7th and 14th days of the experiment, 2 (3) animals of the first group allocated a significant amount of colonies (2-3 tbsp ) Haemophilus influenzae type b. One animal - a single colony in the same part of the respiratory tract. Histological examination in 2 animals (which were isolated colonies of microorganisms in a significant amount) detected changes of the mucosa of the nasopharynx, typical of purulent inflammation (focal dissociation of cells of the epithelial layer of the mucous membrane, marginalia chromatin with cell necrosis, collapse of the epithelial layer, the plethora of vessels, swelling and degenerative changes in some glands necrosis cellular elements).

Animals of the second (control) group in smears from the mucous membrane Obol and 14 days of decapitatin not found. Inflammatory changes in the mucosa of both halves of the nose, ethmoid sinuses, the Oro - and nasopharynx histological examination in the days of its bacteriological studies were not found.

Thus, the results of experiment 1 showed that infection of healthy albino rats culture Haemophilus influenzae type b in solution with a volume of 0.2 cm3containing 500 million microbial cells, in 2 of 3 animals develop bacteriologically and histologically confirmed inflammation in the ethmoid sinuses and nasopharynx.

Experiment 2 was as follows: two groups of animals 9 white rats each were from the first day on lipid diet, technique, A. Vilkova et al. (Vilkov, A., Stepanenko E. M., Kryzhanovsky, N. Effect of vitamin E and timeline on the development of experimental allergic encephalomyelitis/bul. the experimental. Biol. and the honey.- 1987.- N 9.- S. 288-290). Both groups of rats received lipid diet for 21 days period, confirmed by many researchers as optimal for achieving the desired effect. On each cage was preparing the daily food portion weight (90 g not smoked lard weak Ambassador and 10 g cereal flour"). For the preparation of flour use the pieces and mixed with cereal flour in a mechanical grinder and distributed this food mass of 100 grams per cell per day. Thus, each rat was given the required daily amount of feed that to an adult animal is 30-60 grams. The purpose of this diet is a sharp decrease in the reactivity of the organism of experimental animals by reducing the stability of the antioxidant system. The second group of animals was used as control.

On the 4th day of the experiment on the mucous membrane of the nasal cavity of experimental animals of the first group inflicted capsular polysaccharide antigen of Haemophilus influenzae type b in solution with a volume of 0.2 cm3at the rate of 1 mg/ml Injections of antigen in the nasal cavity of each animal of the first group produced 1 every three days for 21 days - a total of 6 times.

After 3 weeks of content on lipid diet in rats of both groups were observed loss of body weight by 15-20%, weakness, yellowing of wool and its loss (signs of hypovitaminosis E), loss of appetite, and severe aggression.

After lipid diets on the 22nd day of the experiment, one half of the nose of each animal in both groups once poured the culture of Haemophilus influenzae type b in solution with a volume of 0.2 cm3contains 500 million microbial phone

The decapitation of the animals (the e demonstration was watch animals in the second (control) group. During the clinical observation of the animals 5 days after infection showed signs of acute rhinosinusitis breathing became more noisy, during the examination found mild narrowing of the nasal passages due to the swelling of the nasal mucosa. In the following days the swelling had increased, within 8 days after infection on the mucous membrane of the nasal cavity appeared a small amount of mucus. When the examination was notable moderate hyperemia of the mucous membrane of the nasal cavity. After 14 days mucous exudates in the nose of the animals were kept in small numbers. Bacteriological examination of the surface of the mucous membranes of the nasal cavity, ethmoid sinuses, and nasopharynx at 7 and 14 days after infection revealed a significant number of colonies of Haemophilus influenzae type b (3 tbsp ), and histological preparations of the mucous membranes of these parts of the respiratory system - the signs of pronounced inflammation in the nasal cavity and ethmoid sinuses and much less pronounced in the nasopharynx.

Clinical observations, bacteriological and histological examination for the animals of the first group in any case, and neither one of these days studies have found manifestations of inflammation in the upper respiratory ptov can conclude that, the introduction of the capsular polysaccharide antigen of Haemophilus influenzae type b can prevent the development of inflammation in the upper respiratory tract even in the group of animals with weakened sharply antioxidant system (the ability to adequately respond to the inflammatory process in the body.

The goal is achieved prior six-time introduction into the nasal cavity capsular polysaccharide antigen of Haemophilus influenzae type b in solution with a volume of 0.2 ml at a rate of 1 mg/ml.

Description of the proposed method.

For the prevention of inflammatory diseases of the upper respiratory tract (caused by Haemophilus influenzae type b) patient intranasally pour 1 time in three days, a total of six times) capsular polysaccharide antigen of Haemophilus influenzae type b in solution with a volume of 0.2 ml at a rate of 1 mg/ml, which is 1 dose.

The proposed method is as follows. Extract from the medical history of the patient K., age 9, N outpatient card 1417, was on outpatient treatment in the ENT's office of the Rostov Regional medical exercises dispensary. From the anamnesis of the disease became known that the patient within 3 years suffer from chronic rhinosinusitis with frequent exacerbations (prieskum difficulty of nasal breathing. 2 years ago was adenotomy that did not affect the nature of the disease and the number of exacerbations. When viewed in the nasal cavity - the mucous membrane of the nasal Concha moderately bluish, slightly swollen, separated in the nasal passages no, nasal breathing freely; in a throat mucosa pink, wet, Palatine tonsils small size, not fused with bows in their lacunae separated not; in the nasopharynx - the mucous membrane scar changed in the area of the mouth of the right auditory tube, adenoid vegetation in the vault there.

The patient in the nasal cavity entered one dose capsular polysaccharide antigen of Haemophilus influenzae type b in solution with a volume of 0.2 ml at a rate of 1 mg/ml. Such instillation of antigen repeated 1 time in three days, making a total of 6 infusions.

Following the examination, the patient was carried out over 1 month - there were no complaints, nasal breathing is free. Subsequent examinations were performed 1 time within 6 months of disease recurrence was not.

The advantages of the proposed method in comparison with the prototype are that can prevent the development of inflammation in the upper respiratory tract, as well as the possibility of complications.

The way p the capsular polysaccharide antigen of Haemophilus influenzae type b, wherein the capsular polysaccharide antigen of Haemophilus influenzae type b is administered intranasally six times 1 time in three days in the dose of 0.2 ml at a rate of 1 mg/ml

 

Same patents:

The invention relates to medicine, in particular to Pediatrics

The invention relates to medicine, in particular to Pediatrics

The invention relates to new, containing diazepambuy group of compounds with biological activity, and more particularly to a derivative of diazepinone, their racemic forms, their isomeric configurations defined by the carbon in position 3 diazepinone-4-about the kernel and their pharmacologically acceptable salts, intermediate compounds and pharmaceutical compositions inhibiting phosphodiesterase IV activity
The invention relates to medicine, namely to physiotherapy

The invention relates to the field of biochemical pharmacology and medicinal chemistry

The invention relates to new derivatives naphthiridine formula I, where R1denotes phenyl, benzyl, 3-nitrophenyl, 3-chlorophenyl, 3-tianfeng, 3-(tetrazolyl)phenyl or benzofuranyl; R2denotes a hydroxy-group, tripterocalyx, allyl, alkyl, alkenyl, quinil, alkoxygroup, phenyl, phenyloxy, carboxyphenyl, carboxymethyl, carbamoylmethyl, phenylamino, diphenylamino-, amino-, elcamino, Alcaidaria, where "ALK" refers to aliphatic fragment having up to 8 carbon atoms and optionally including carboxylate, ether carboxylic acid or a hydroxy-group and/or optionally containing ether and/or ester bond, or its N-oxide in free form or in the form of a pharmaceutically acceptable salt

The invention relates to medicine, namely to the combined drug, possess expectorant, anti-inflammatory and antiallergic effect, and can be used in complex therapy of inflammatory diseases of the Airways and lungs

The invention relates to new ascomycin General formula I, where Y represents a phenylene; Z is selected from carboxyl and physiologically hydrolyzable of oxycarbonyl or alkyl, CNS, alkylamino or dialkylamino bearing from 1 to 4 carboxyl or physiologically hydrolyzable oxycarbonyl group; Q is O or S; R1Is H, alkyl or aryl; R2is hydrogen or hydroxyl; R3is methyl, ethyl, propyl or allyl; R4is hydroxyl or alkoxyl; R5-oxoprop or (H, OH), R6- oxoprop, H, HE H, alkoxyl); n is an integer 1 or 2, in free form or in the form of a pharmaceutically acceptable salt

The invention relates to medicine, namely to clinical phototherapy, and can be used for treatment of bronchial asthma

The invention relates to the field of veterinary Microbiology and can be used in the development and production of specific prevention of pasteurellosis animals and birds

The invention relates to biotechnology and can be used in industrial production of live and inactivated vaccine against pasteurellosis animals and birds

The invention relates to biotechnology and can be used in industrial production of vaccine against pasteurellosis of agricultural animals and birds

The invention relates to veterinary Microbiology, in particular the production of therapeutic sera against hemophilia, streptococcosis and swine pasteurellosis

Adjuvant // 2108111
The invention relates to the field of biotechnology, veterinary Virology and Microbiology, and more particularly to an oil adjuvant, and can be used in the development and production of immunizing preparations for the diagnosis and prevention of infectious diseases in different species of farm animals

The invention relates to veterinary Microbiology, namely, for construction of bacterial vaccines for the prevention of Streptococcus and pasteurellosis nutria

The invention relates to veterinary Microbiology, namely, for construction of bacterial vaccines for the prevention of Streptococcus and pasteurellosis nutria
The invention relates to methods for hyperimmune sera against Pasteurella multocida used for treatment of animals

The invention relates to the field of the biotechnology industry, in particular the production of virus-inducer for the production of human leukocyte interferon
Up!